Mesalamine with MMX technology for the treatment of ulcerative colitis. - Wikidata - wikimedia - TriplyDB

Mesalamine with MMX technology for the treatment of ulcerative colitis.

Mesalamine with MMX technology for the treatment of ulcerative colitis.

http://www.wikidata.org/entity/Q37345925

about

New Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence Balsalazide in treating colonic diseases.eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.

P2860

Q33916287-C9576D5D-A477-4D5D-9A77-F1C1D816AA60 Q37587217-6C672E25-A699-4677-8A6B-E7EDCB8F6334 Q48064807-353313EB-C3FD-46BC-9F6D-F077885AE078

P2860

Mesalamine with MMX technology for the treatment of ulcerative colitis.

http://www.wikidata.org/entity/Q37345925

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Mesalamine with MMX technology for the treatment of ulcerative colitis.

@en

Mesalamine with MMX technology for the treatment of ulcerative colitis.

@nl

type

label

Mesalamine with MMX technology for the treatment of ulcerative colitis.

@en

Mesalamine with MMX technology for the treatment of ulcerative colitis.

@nl

prefLabel

Mesalamine with MMX technology for the treatment of ulcerative colitis.

@en

Mesalamine with MMX technology for the treatment of ulcerative colitis.

@nl

P1433

Q37345925-A8C1D69B-A257-4B04-9F29-D6BD95F8E874

P1476

Q37345925-E0C7BB15-C674-4E21-BD6F-78A001BFF3A4

P2093

Q37345925-06A063A7-A7DB-4E9C-9CBC-6122CF228DC4

Q37345925-7E0FD3FA-0A4C-42DB-9E18-6F9DEBC8DECE

Q37345925-ADDFC0F6-9E7A-4E9F-B7A7-3CF1C2B779D3

P2860

Q37345925-0034B574-FA3B-45E0-B2A5-571F387F2741

Q37345925-070A51E5-30D7-499E-ABD4-2E141E731FD4

Q37345925-07596D6E-1DF0-40E7-8FAD-60673B761F46

Q37345925-0A41B164-CFFE-4428-8D11-A1B7CEDCD1E2

Q37345925-0B900560-665E-4F4D-948A-EC61402898F2

Q37345925-14407E3F-B7D3-4B6E-8EF5-33B2ADFF13EF

Q37345925-144E28B2-B9E7-41CE-997F-4AA0A49FEFFE

Q37345925-18FB32A2-2586-4127-9EBB-4AF5B75C394E

Q37345925-1A92A69A-DB17-4323-90AD-CD867AACED8D

Q37345925-1ABD2484-89F1-479B-A3A7-C6F38DD2C5B3

P304

Q37345925-0F446A63-6FE3-4B4D-9DD8-FD9B37063BB4

P31

Q37345925-38B55829-BBF9-47B6-9B68-DD273BE5D861

P356

Q37345925-49FD449F-C9AB-451D-8437-1550BF3A9F8C

P433

Q37345925-19D1118E-3A44-42FB-8CED-D4D17E2B74FC

P478

Q37345925-9E000C18-C733-4830-AD9D-621BFB7AFD38

P577

Q37345925-78A8C620-A255-4A6D-AA4A-2A35B97F67AD

P698

Q37345925-A412E8C8-D20F-4125-AE6E-C21550BF86C0

P356

17474124.2.3.299

P1433

Expert Review of Gastroenterology & Hepatology

P1476

Mesalamine with MMX technology for the treatment of ulcerative colitis.

@en

P2093

Gary R Lichtenstein

http://www.w3.org/2001/XMLSchema#string

Michael A Kamm

http://www.w3.org/2001/XMLSchema#string

Stefan Schreiber

http://www.w3.org/2001/XMLSchema#string

P2860

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs

Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes.

Ulcerative colitis.

Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.

5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease

Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations.

Drug induced acute pancreatitis: incidence and severity.

P304

299-314

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474124.2.3.299

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19072380

http://www.w3.org/2001/XMLSchema#string